Stay updated with breaking news from Anders Kronborg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022. Tralokinumab is marketed outside of the U.S. under the
LEO Pharma A/S, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved Adbry™ (tralokinumab) ...
With FDA approval for its atopic dermatitis drug Adbry, LEO Pharma will reach the U.S market ahead of an Eli Lilly atopic dermatitis drug that addresses the same target. LEO will also able to offer patients an alternative to the blockbuster Sanofi/Regeneron Pharmaceuticals drug Dupixent.